Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $17.2 million, down from $83.7 million in the prior year quarter, and full year revenue was $42.7 million compared to $108.3 million in 2024, primarily due to the termination of the Takeda collaboration [25][26] - Research and development expenses increased to $52.8 million in Q4 2025 from $44.6 million in Q4 2024, and for the full year, R&D expenses were $182.8 million compared to $159.7 million in 2024 [25][26] - The net loss for Q4 2025 was $53.2 million, compared to a net income of $29.3 million in the prior year quarter, and the full year net loss was $204.4 million compared to a net loss of $97 million in 2024 [27] Business Line Data and Key Metrics Changes - The company is focusing on two main programs: WVE-007 for obesity and WVE-006 for alpha-1 antitrypsin deficiency (AATD), with significant advancements in both areas [5][14] - WVE-007 showed promising interim data with a placebo-adjusted 4% reduction in total fat and a 9.2% reduction in visceral fat after three months at the lowest therapeutic dose [21] - WVE-006 demonstrated the ability to restore M-AAT protein levels to therapeutically meaningful levels, with over 11 micromolar protein and greater than 50% editing achieved [16] Market Data and Key Metrics Changes - The obesity treatment market is evolving, with a shift towards therapies that focus on body composition rather than just weight loss, highlighting the need for innovative mechanisms beyond current options like GLP-1s [7][13] - The company aims to address the unmet needs in the AATD market, where current treatment options are limited, and there is a significant patient population in need of effective therapies [14][15] Company Strategy and Development Direction - The company is strategically focused on accelerating the development of WVE-007 and advancing its RNA editing portfolio, with plans to initiate new clinical trials in 2026 [28] - There is a recognition of the need for novel obesity mechanisms and therapeutics, with WVE-007 positioned as a potential game-changer in the obesity landscape due to its unique dosing regimen and safety profile [13][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing clinical trials and the potential for WVE-007 and WVE-006 to meet significant unmet medical needs, with expectations for regulatory feedback on accelerated approval pathways by mid-2026 [32][42] - The company is optimistic about the future, aiming to unlock the full potential of its RNA medicines pipeline to transform human health [28] Other Important Information - The company ended 2025 with $602.1 million in cash and cash equivalents, which is expected to fund operations into the third quarter of 2028 [27] - The collaboration with GSK is progressing, with potential milestone payments expected in 2026 and beyond [18] Q&A Session Summary Question: How closely does your regulatory strategy mirror a competitor's recent alignment with the FDA? - Management indicated that their regulatory strategy is aligned with existing therapies for AATD, focusing on a biomarker approach and anticipates positive discussions with the FDA [31][32] Question: Will there be data updates for the 400 mg multi and 600 mg single doses? - Management confirmed that data is on track and will be included in the next update, emphasizing the ongoing data collection from the study [36][37] Question: What are the expectations for confirmatory trial requirements for AATD? - Management stated that they aim to establish an accelerated approval pathway for AATD patients and will align with the agency on the necessary requirements [42][43] Question: What outcomes data are planned to minimize potential payer pushbacks for obesity treatment? - Management highlighted the importance of demonstrating significant fat loss and lean mass preservation to support regulatory pathways and address payer concerns [48][50] Question: What treatment delta is expected for MRI-PDFF in the upcoming obesity trial? - Management noted that there is a substantial opportunity for liver fat reduction and emphasized the importance of monitoring these outcomes in the context of MASH [65][66]

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $7.6 million compared to a net loss of $7.7 million in the prior year quarter, attributed to the timing of revenue recognized under the collaboration agreement with GSK [22] - Research and development expenses increased to $45.9 million from $41.2 million year-over-year, driven by advancements in the inhibin E and RNA editing programs [22] - General and administrative expenses rose to $18.1 million from $15 million in the prior year quarter, primarily due to share-based compensation [22] - Net loss for Q3 2025 was $53.9 million, an improvement from a net loss of $61.8 million in the prior year quarter [23] - Cash and cash equivalents at the end of Q3 2025 were $196.2 million, down from $302.1 million as of December 31, 2024, but extended cash runway into Q2 2027 with additional proceeds [24] Business Line Data and Key Metrics Changes - The company highlighted significant advancements in the WVE-007 program, showing dose-dependent reductions in activin E levels, with reductions of 56%, 75%, and 85% for different dosing cohorts [8][9] - WVE-006 demonstrated the potential to restore physiological AAT production, achieving AAT levels of up to 13 micromolar and a 60% decrease in mutant ZAAT protein [13] - The DMD program, WVEN531, showed a statistically significant improvement in time to rise, with a 3.8 seconds improvement compared to natural history [18] Market Data and Key Metrics Changes - The company is addressing a significant market need with an estimated 9 million homozygous individuals living with PNPLA3I148M liver disease in the US and Europe, who are at a nine-fold higher risk of dying from their liver disease compared to non-carriers [16] - The obesity market is highlighted as having over 1 billion individuals living with obesity, many of whom lack access to current GLP-1 therapies, presenting a unique opportunity for the company's treatments [55] Company Strategy and Development Direction - The company is focused on advancing its pipeline, particularly in RNAi and RNA editing, with a strategy to leverage proprietary chemistry and platform innovations [5] - There is a strong emphasis on developing non-incretin treatment approaches for obesity, with WVE-007 positioned as a potential maintenance therapy to prevent rebound weight gain [6][11] - The company aims to build on its momentum in the obesity space, with plans for further studies and potential partnerships to enhance development [43] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the progress made in clinical trials, particularly with WVE-007 and WVE-006, and the potential for these therapies to transform treatment paradigms [25] - The management team acknowledged the competitive landscape in the obesity market and the need for innovative solutions that provide durable results without the side effects associated with current therapies [55] - There is confidence in the ability to meet regulatory requirements and achieve clinical milestones, with ongoing discussions with the FDA regarding imaging endpoints for Huntington's disease [29][30] Other Important Information - The company is preparing for a global potentially registrational phase 2-3 study of WVE-003 in adults with Huntington's disease, using caudate volume as a primary endpoint [19] - The company has received positive feedback from key opinion leaders regarding the potential of its RNA editing programs to address unmet medical needs [14] Q&A Session Summary Question: Inquiry about cholesterol fat mobilization post-inhibin knockdown - Management confirmed no observed changes in increased lipids and deposits in the liver from preclinical studies, indicating positive findings regarding fat mobilization [26][27] Question: Pre-IND meeting with FDA regarding Huntington's imaging endpoints - Management confirmed alignment with the FDA on using MRI as an imaging endpoint, emphasizing the importance of well-designed clinical trials [29] Question: Changes in gene expression timing in obesity studies - Management noted that while gene expression changes occur over time, early engagement of targets and sustained suppression of proteins are observed [34] Question: Insights on acute phase response in AATD patient - Management indicated that the patient responded as expected, with no new insights beyond the initial findings [48] Question: Future studies beyond NYTE for obesity program - Management expressed interest in exploring further studies and potential strategic partnerships, while noting that the GSK collaboration would not hinder these opportunities [62]